MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy

Table 1

Baseline Clinical and Demographic characteristics of the study cohort.

Variable	Total	PCa			csPCa
		NO	YES	p value	NO	YES	p value
Patients, No. (%)	231 (100)	156 (67.5)	75 (32.5)		172 (74.5)	59 (25.5)
Interval, Median (IQR),; m	20.1; (7.9-37.0)
Age, Mean ± SD, years	69.03 ± 7.05	67.19 ± 6.60	72.87 ± 6.41	< 0.001	67.53 ± 6.68	73.42 ± 6.25	<0.001
BMI, Mean ± SD, kg/ml	23.93 ± 2.79	23.90 ± 2.69	24.00 ± 3.00	0.796	23.85 ± 2.71	24.16 ± 3.01	0.476
PSA, Median (IQR),; ng/ml	15.03; (10.03-23.15)	13.44; (9.44-17.93)	22.32; (13.77-36.89)	< 0.001	13.44; (9.48-18.59)	24.43; (15.89-42.84)	<0.001
f/t, Mean ± SD, %	0.14 ± 0.06	0.14 ± 0.06	0.12 ± 0.07	0.016	0.14 ± 0.06	0.12 ± 0.07	0.007
PV, Mean ± SD, ml	71.69 ± 42.41	80.92 ± 46.04	52.48 ± 24.40	< 0.001	79.35 ± 45.25	49.36 ± 20.34	<0.001
PSAD, Median (IQR),; ng/ml/ml	0.25; (0.15-0.45)	0.19; (0.12-0.29)	0.51; (0.25-0.76)	< 0.001	0.20; (0.12-0.30)	0.58; (0.33-0.79)	<0.001
PSAV, Median (IQR),; ng/ml/yr	1.55; (0.12-5.43)	1.06; (-0.64-3.74)	4.04; (1.38-8.60)	< 0.001	1.11; (-0.24-4.04)	5.29; (1.52-9.09)	< 0.001
DRE, No. (%)				< 0.001			< 0.001
Normal	198 (85.7)	143 (91.7)	55 (73.3)		157 (91.3)	41 (69.5)
Abnormal	33 (14.3)	13 (8.3)	20 (26.7)		15 (8.7)	18 (30.5)
TRUS, No. (%)				0.017			0.005
Negative	179 (77.5)	128 (82.1)	51 (68.0)		141 (82.0)	38 (64.4)
Positive	52 (22.5)	28 (17.9)	24 (32.0)		31 (18.0)	21 (35.6)
mpMRI, No. (%)				< 0.001			< 0.001
Negative	148 (64.1)	125 (80.1)	23 (30.7)		136 (79.1)	12 (20.3)
Suspicious	31 (13.4)	16 (10.3)	15 (20.0)		18 (10.5)	13 (22.0)
Positive	52 (22.5)	15 (9.6)	37 (49.3)		18 (10.5)	34 (57.6)

PCa, prostate cancer; csPCa, clinically significant prostate cancer; IQR, interquartile range; SD, standard deviation; BMI, body mass index; PSA, prostate-specific antigen; f/t, free/total PSA ratio; PV, prostate volume; PSAD, PSA density; PSAV, PSA velocity; DRE, digital rectal examination; TRUS, transrectal ultrasound; mpMRI, multi-parametric magnetic resonance imaging.